201 related articles for article (PubMed ID: 29444778)
1. Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial.
Tian PP; Li J; Gao J; Li Y
BMJ Open; 2018 Feb; 8(2):e018052. PubMed ID: 29444778
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Shexiang Baoxin Pill combined with Western medicine in the treatment of acute myocardial infarction: A single-center, double-blind, randomized controlled trial.
Yang Y; Gao S; Fang Q; Zhu M
Medicine (Baltimore); 2021 Jan; 100(3):e24246. PubMed ID: 33546045
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.
Ge JB; Fan WH; Zhou JM; Shi HM; Ji FS; Wu Y; Zhao YL; Qian J; Jin YZ; Liu YW; Wang SH; He SH; Yang P; Wu J; Lu F; Hou ZS
Chin Med J (Engl); 2021 Jan; 134(2):185-192. PubMed ID: 33273369
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of Chinese herbal medicine xuanbi antong granules for the treatment of borderline coronary lesions: study protocol for a randomised, double-blinded, placebo-controlled, multicentre clinical trial.
Huang M; Chen G; Guan Q; Liu C; Zhao Q; Li J; Yao K; Zhang Z; He H; Li Y; Lin F; He X; Liu Y; Xiong XJ; Zhang Y; Han M; Wang J
BMJ Open; 2019 Aug; 9(8):e024968. PubMed ID: 31399446
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of Shexiang Baoxin Pill (MUSKARDIA) as the add-on treatment to standard therapy for stable coronary artery disease in China.
Pan J; Ping PD; Wang W; Zhou JM; Zhu WT
PLoS One; 2024; 19(3):e0299236. PubMed ID: 38427636
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of
Wu T; Li S; Li Z; Long W; Liu Q; Tang H; Huang X; Tang Y; Dong X; Ning Y; Tian S; Xu T; Xian SX; Liao H; Hong Y; Yang Z
BMJ Open; 2023 May; 13(5):e055263. PubMed ID: 37164472
[TBL] [Abstract][Full Text] [Related]
7. Effects of Danlou tablet for the treatment of stable angina pectoris: A study protocol of a randomized, double-blind, and placebo-controlled clinical trial.
Yang G; He H; Li H; Shen Z; Zhou S; Lu B; Li J; He Q; Zhang Z; Liu Y; Wang J; Chen H
Medicine (Baltimore); 2020 Dec; 99(49):e23416. PubMed ID: 33285733
[TBL] [Abstract][Full Text] [Related]
8. A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review.
Zhou Z; Shen W; Yu L; Xu C; Wu Q
J Ethnopharmacol; 2016 Dec; 194():1130-1139. PubMed ID: 27847338
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
10. [Network Meta-analysis of Chinese patent medicines in treatment of coronary heart disease complicated with heart failure].
Wang AL; Wei JJ; Sun Y; Guo HX; Zhang MJ; Lu JF; Zhang YL; Peng GC; Zhu MJ
Zhongguo Zhong Yao Za Zhi; 2024 Jan; 49(2):518-533. PubMed ID: 38403327
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled clinical study on Yiqi Liangxue Shengji prescription for intervention cardiac function of acute myocardial infarction with ischemia-reperfusion injury.
Chen C; Xia J; Feng R; Wan J; Zhou K; Lin Q; Li D
Medicine (Baltimore); 2021 Mar; 100(10):e24944. PubMed ID: 33725857
[TBL] [Abstract][Full Text] [Related]
12. Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial.
Li S; Guo M; Mao H; Gao Z; Xu H; Shi D
Trials; 2016 Sep; 17(1):451. PubMed ID: 27628038
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial.
Zhou J; Shi H; Ji F; Wu Y; Zhao Y; Qian J; Ge J
Chin Med J (Engl); 2023 Jan; 136(1):82-87. PubMed ID: 36752805
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the Chinese herbal medicine Bu-Shen-Huo-Xue granule for the treatment of coronary heart disease: study protocol for a multicenter, randomized, double-blinded, placebo-controlled clinical trial.
Liu L; Wang J; Li J; Li X; Li R; Liu Y; Yang G; Mao Q; Wang L; Yao Z; Wang Y; Zong S; Liu C
Front Cardiovasc Med; 2024; 11():1293818. PubMed ID: 38895537
[TBL] [Abstract][Full Text] [Related]
15. [Network Meta-analysis of oral Chinese patent medicines in treating type 2 diabetes mellitus complicated with angina pectoris of coronary heart disease].
Zhang XM; Zhao XX; Liu Y; Xie YM
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):5078-5090. PubMed ID: 37802850
[TBL] [Abstract][Full Text] [Related]
16. Serum proteomic analysis reveals the cardioprotective effects of Shexiang Baoxin Pill and Suxiao Jiuxin Pill in a rat model of acute myocardial infarction.
Song N; Lu D; Wu G; Wang S; Zeng Y; Zhao J; Meng Q; He H; Chen L; Zhu H; Liu A; Li H; Shen X; Zhang W; Zhou H
J Ethnopharmacol; 2022 Jul; 293():115279. PubMed ID: 35405256
[TBL] [Abstract][Full Text] [Related]
17. Multicentre, open-label, randomised controlled clinical trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild-to-moderate stenotic lesions with high-risk plaques in coronary arteries: study protocol.
Matsuda M; Kada A; Saito AM; Hasegawa K
BMJ Open; 2019 Jan; 9(1):e022843. PubMed ID: 30782687
[TBL] [Abstract][Full Text] [Related]
18. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial.
Guo M; Wang P; Du J; Fu C; Yang Q; Gao Z; Zhu M; Lv S; Deng Y; Li T; Shi D; Working Group FTX
Pharmacol Res; 2020 Aug; 158():104883. PubMed ID: 32446979
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation on tolerability and safety of long-term administration with shexiang baoxin pill in patients with coronary heart disease of stable angina pectoris].
Wang LJ; Luo XP; Wang Y
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 May; 28(5):399-401. PubMed ID: 18672763
[TBL] [Abstract][Full Text] [Related]
20. Shexiang Baoxin Pill enriches Lactobacillus to regulate purine metabolism in patients with stable coronary artery disease.
Wu G; Liao J; Zhu X; Zhang Y; Lin Y; Zeng Y; Zhao J; Zhang J; Yao T; Shen X; Li H; Hu L; Zhang W
Phytomedicine; 2024 Jul; 130():155727. PubMed ID: 38781732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
